KFDA approves additional indication of Janumet

The Korea Food and Drug Administration has recently approved the additional indication of Janumet (sitagliptin+metformin), the first and only tablet combining a dipeptidyl peptidase-4 (DPP-4) inhibitor, for the treatment of type 2 diabetes.

The approved indication is the co-administration of Janumet with insulin or TZD.

So far, Zanumet has been indicated, as an adjunct to diet and exercis...